Pharmacy Website
    Clinic Website

    Intelligence » Amyotrophic Lateral Sclerosis » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    REGENERON PHARMACEUTICALS, INC.: FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy

    Sunday, September 16, 2018 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) of EYLEA® (aflibercept) Injection for the treatment of diabetic retinopathy (DR), the leading cause of vision loss for patients with diabetes. Read more..

    New 15-Item Dyspnea-ALS-Score Assesses Dyspnea in ALS

    Wednesday, September 19, 2018 -- The novel questionnaire may identify patients with ALS suffering from dyspnea and allow early assessment and monitoring for symptom management.